Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Current immunotherapy for advanced non-small-cell lung cancer (NSCLC), primarily using PD-1/PD-L1 inhibitors, shows limited response rates and short progression-free survival.
• Tumor PD-L1 expression via immunohistochemistry (IHC) is the standard biomarker, but its predictive value is insufficient.

Purpose of the Study:

• To review diverse biological facets of NSCLC beyond PD-L1 expression.
• To explore novel concepts and potential biomarkers for enhancing immunotherapy efficacy in NSCLC.
• To re-evaluate the role of PD-L1 IHC as a biomarker in light of new findings.

Main Methods:

• Comprehensive literature review of NSCLC biology, including genetic alterations, immune evasion mechanisms, and cell death pathways.
• Analysis of emerging concepts such as immune-transmitters, neurotransmitter effects, necroptosis, pyroptosis, and metabolic rewiring.
• Discussion of novel biomarkers like gasdermin D/E and the significance of K-Ras/LKB1 mutations.

Main Results:

• Identified numerous biological factors influencing NSCLC progression and immunotherapy response, including driver mutations, PD-L1 glycosylation, ferroptosis, and metabolic pathways.
• Highlighted the role of immune-transmitters, neurotransmitters, necroptosis, and pyroptosis in immune evasion and tumor growth.
• Presented evidence suggesting the PDCD1 gene (PD-1) and its equilibrium with PD-L1 may explain tumor hyper-progression, questioning IHC PD-L1's sole biomarker status.

Conclusions:

• Effective immunotherapy in NSCLC requires a deeper understanding of diverse signaling pathways and biological facets.
• Novel biomarkers and a revised approach to PD-L1 assessment are crucial for optimizing treatment strategies.
• Exploring new therapeutic avenues targeting metabolic rewiring and cell death pathways holds promise for improving patient outcomes.